Allergan, Inc. 

(Public, NYSE:AGN)   Watch this stock   
Find more results for agn
Oct 29, 2009
Q3 2009 Conference Call
Oct 29, 2009
Q3 2009 Release
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 15.70% 13.18%
Operating margin 20.72% 18.08%
EBITD margin - 24.08%
Return on average assets 10.12% 8.68%
Return on average equity 16.15% 14.93%
Employees 8,000 -

Address

2525 Dupont Drive
Irvine, CA 92612
United States - Map
+1-714-2464500 (Phone)
+1-714-2464971 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
About Company - Wikipedia

Allergan, Inc. discussed on blogs

Dan Loeb's Third Point Starts New Stakes In Popular (BPOP ... - marketfolly@gmail.com (Market Folly) - market folly - Nov 19, 2009

Allergan, Inc. discussions

  View all discussions »

Description

Allergan, Inc. is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics and medical devices. The Company is engaged in discovering, developing and commercializing specialty pharmaceutical, medical device and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in more than 100 countries globally. In January 2007, the Company completed the acquisition of Groupe Corneal Laboratoires (Corneal). In October 2007, the Company completed the acquisition of Esprit Pharma Holding Company, Inc. (Esprit). In July 2008, the Company acquired the Aczone (dapsone) gel 5% from QLT USA, Inc. (QLT), a wholly owned subsidiary of QLT Inc. The Company operates in two business segments: specialty pharmaceuticals and medical devices.

Officers and directors

David E. I. Pyott
Chairman of the Board, Chief Executive Officer, Principal Executive Officer
Age: 55
Bio & Compensation - Reuters
F. Michael Ball
President
Age: 53
Bio & Compensation - Reuters
Herbert W. Boyer Ph.D.
Vice Chairman of the Board
Age: 72
Bio & Compensation - Reuters
Jeffrey L. Edwards
Chief Financial Officer, Executive Vice President - Finance and Business Development
Age: 48
Bio & Compensation - Reuters
Douglas S. Ingram Esq.
EVP, Chief Administrative Officer, General Counsel, Secretary, Chief Ethics Officer
Age: 46
Bio & Compensation - Reuters
Dianne Dyer-Bruggeman
Executive Vice President - Human Resources
Age: 59
Bio & Compensation - Reuters
Scott M. Whitcup M.D.
Executive Vice President - Reseach & Development
Age: 49
Bio & Compensation - Reuters
Raymond H. Diradoorian
Executive Vice President - Global Technical Operations
Age: 51
Bio & Compensation - Reuters
James F. Barlow
Senior Vice President, Corporate Controller, Principal Accounting Officer
Age: 50
Bio & Compensation - Reuters
Gavin S. Herbert
Chairman Emeritus
Age: 76
Bio & Compensation - Reuters